ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1360

Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort

Yvette Meissner1, Bernhard Eickhoff1, Cornelia Glaser2, Joerg Henes3, Jutta Richter4, Susanna Spaethling-Mestekemper5, Christof Specker6, Rebecca Fischer-Betz4 and Anja Strangfeld1, 1German Rheumatism Research Center, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology University Medical Center Freiburg, Freiburg, Germany, 3University Hospital Tuebingen, Tuebingen, Germany, 4Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Düsseldorf, Germany, 5Rheumapraxis Muenchen, Muenchen, Germany, 6Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Essen, Germany

Meeting: ACR Convergence 2023

Keywords: Anxiety, Autoinflammatory diseases, Patient reported outcomes, pregnancy, registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pregnancies in women with chronic diseases are often accompanied by concerns about potential complications [1]. This analysis explored medication-related concerns among women with inflammatory rheumatic disease (IRD) and identified influencing factors.

[1] PMID: 26039501

Methods: The German registry Rhekiss is a nationwide, multicentre, web-based cohort study to investigate pregnancies in women with various IRD. Women can participate if they are either planning a pregnancy (cohort 1) or are already pregnant (up to 20 weeks of gestation; cohort 2). Rheumatologist- and patient-reported data are captured at regular, pre-defined follow-up visits.

We analysed data of women who had responded to a question about concerns regarding pregnancy and child’s health in relation to medication. Categorical answers and patient characteristics were analysed descriptively. The impact of factors associated with patients’ anxieties was estimated by multivariable ordinal logistic regression using the proportional odds model and combining the two cohorts. Missing values were replaced by single imputation.

Results: Between 09/2015 and 10/2022, a total of 2,240 patients were enrolled (cohort 1: 708, cohort 2: 1,532). Out of those, n=455 and n=784, respectively, were eligible for the analysis.On average, women were 32-33 years old and disease duration was 7-11 years (table).A total of 34% in cohort 1 and 25% in cohort 2 stated that they are concerned “a lot” (figure). Responses varied across different IRD diagnoses.

Treatment changes had the greatest impact on higher levels of worries, (odds ratio 1.72 [95% confidence interval 1.38; 2.14]). Furthermore, a significant association was found for moderate-severe IRD (1.34 [1.17; 1.53]) and a higher disease impact, measured by patient-reported RAID score (per 1-point-increase: 1.31 [1.24; 1.38]). Patients who were already pregnant at enrolment were less worried than patients planning a pregnancy (0.63 [0.51; 0.79]). No significant relationship was found for maternal age, number of prior pregnancies and comorbidities.

Conclusion: At least one in four women with IRD is “very concerned” about pregnancy and infant health due to medications. Treatment changes, moderate-severe disease and higher RAID score were associated with higher levels of concern. Therefore, worries should be an essential part of individual counselling for patients who either wish to become pregnant or are already pregnant.


Funding:
Rhekiss is jointly funded by the German Rheumatism Research Centre Berlin and the Rheumazentrum Rhein-Ruhr e.V., Düsseldorf.

Supporting image 1

Table: Characteristics of patients stratified by level of concern.

Supporting image 2

Figure: Level of concerns stratified by cohort and by IRD diagnosis.


Disclosures: Y. Meissner: Eli Lilly, 6, Pfizer, 6; B. Eickhoff: None; C. Glaser: Galapagos, 6, Novartis, 6, Pfizer, 6, UCB, 5, 6; J. Henes: AbbVie/Abbott, 2, 6, Boehringer-Ingelheim, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, GlaxoSmithKlein(GSK), 2, 6, Janssen, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; J. Richter: None; S. Spaethling-Mestekemper: Abbvie, 6, Astra Zeneca, 6, Bristol-Myers Squibb(BMS), 6, Galapagos, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Lilly, 6, Novartis, 6, Sanofi, 6, UCB, 6; C. Specker: AbbVie, 2, 6, Boehringer-Ingelheim, 2, 6, Bund Deutscher Internisten, 6, Chugai, 2, 6, Eli Lilly, 2, 6, GlaxoSmithKlein(GSK), 2, 6, Janssen-Cilag, 6, Med Update, 6, Merck/MSD, 2, 6, Novartis, 2, 6, Otsuka, 6, Pfizer, 6, Rheumatologische Fortbildungsakademie, 6, Rheumazentrum Rhein-Ruhr, 6, Roche, 6, Sanofi, 6, Sobi, 2, StreamedUp, 6, UCB, 2, Vifor, 6; R. Fischer-Betz: None; A. Strangfeld: AbbVie/Abbott, 6, Amgen, 6, Bristol-Myers Squibb(BMS), 6, Celltrion, 6, Eli Lilly, 6, Janssen, 6, Pfizer, 6, Roche, 6, Sanofi, 6, UCB, 6.

To cite this abstract in AMA style:

Meissner Y, Eickhoff B, Glaser C, Henes J, Richter J, Spaethling-Mestekemper S, Specker C, Fischer-Betz R, Strangfeld A. Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-medication-related-concerns-in-women-with-inflammatory-rheumatic-diseases-an-analysis-of-a-nationwide-pregnancy-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-medication-related-concerns-in-women-with-inflammatory-rheumatic-diseases-an-analysis-of-a-nationwide-pregnancy-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology